CIBC World Markets Inc. decreased its holdings in Chemours Company (The) (NYSE:CC) by 19.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,578 shares of the specialty chemicals company’s stock after selling 7,257 shares during the quarter. CIBC World Markets Inc.’s holdings in Chemours Company (The) were worth $1,122,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of CC. Janney Montgomery Scott LLC purchased a new position in shares of Chemours Company (The) in the first quarter worth approximately $296,000. Oregon Public Employees Retirement Fund purchased a new position in shares of Chemours Company (The) in the first quarter worth approximately $568,000. Wells Fargo & Company MN boosted its holdings in shares of Chemours Company (The) by 21.7% in the first quarter. Wells Fargo & Company MN now owns 331,492 shares of the specialty chemicals company’s stock worth $12,762,000 after buying an additional 59,003 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of Chemours Company (The) by 630.3% in the first quarter. Canada Pension Plan Investment Board now owns 103,700 shares of the specialty chemicals company’s stock worth $3,992,000 after buying an additional 89,500 shares during the last quarter. Finally, First Trust Advisors LP boosted its holdings in shares of Chemours Company (The) by 51.5% in the first quarter. First Trust Advisors LP now owns 163,136 shares of the specialty chemicals company’s stock worth $6,281,000 after buying an additional 55,427 shares during the last quarter. 72.90% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Chemours Company (The) (CC) Shares Sold by CIBC World Markets Inc.” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/16/chemours-company-the-cc-shares-sold-by-cibc-world-markets-inc.html.

CC has been the topic of a number of research reports. ValuEngine raised shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $48.00 price objective on shares of Chemours Company (The) in a report on Friday, June 16th. Citigroup Inc. raised shares of Chemours Company (The) from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $43.00 to $45.00 in a report on Wednesday, July 5th. BidaskClub raised shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Wednesday, July 12th. Finally, Argus reissued a “buy” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Chemours Company (The) in a report on Thursday, August 10th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Chemours Company (The) presently has an average rating of “Buy” and a consensus target price of $51.50.

Chemours Company (NYSE CC) opened at 50.36 on Friday. The firm’s 50-day moving average is $49.94 and its 200 day moving average is $42.84. Chemours Company has a one year low of $14.07 and a one year high of $51.59. The stock has a market cap of $9.31 billion, a P/E ratio of 32.96 and a beta of 3.64.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the company earned $0.27 EPS. Chemours Company (The)’s quarterly revenue was up 14.8% on a year-over-year basis. On average, analysts anticipate that Chemours Company will post $3.51 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Thursday, August 17th were issued a $0.03 dividend. The ex-dividend date was Tuesday, August 15th. This represents a $0.12 annualized dividend and a yield of 0.24%. Chemours Company (The)’s dividend payout ratio (DPR) is presently 8.11%.

In other news, insider E Bryan Snell sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $46.24, for a total transaction of $462,400.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP David C. Shelton sold 13,337 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $48.48, for a total transaction of $646,577.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,837 shares of company stock worth $1,865,603. 1.14% of the stock is owned by corporate insiders.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.